Abstract
Off-label prescribing is the use of a medicinal product outside the conditions set out in the summary of product characteristics and should only be undertaken if there is no licensed alternative available to achieve the best outcome. New evidence that emerges after a licence has been prescribed does not necessarily mean there will be an application for the licence to be extended. Randomised controlled trials based on a homogenised population may not represent the complexities of an individual patient. Therefore, prescribers need to consider a definition of evidence-based prescribing that extends beyond best research evidence to incorporate clinical expertise and individual needs and perspectives of patients. Nurse prescribers should ensure that their competence and expertise to prescribe off-label is addressed to deliver true evidence-based prescribing. An audit of off-label prescribing by nurse prescribers is a potential wealth of evidence yet to be discovered.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
